Page 37 - Cell Line News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate   BERLIN, Germany, April 26, 2021 / B3C newswire / --ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale. ProBioGen will now advance the development of Asher's lead candidate in immuno-oncology applying its unique transposase technology DirectedLuck™ which greatly accelerates time-to-clinic. Asher Biotherapeutics, a ...

CityU researchers identify super-enhancers that stimulate the activity of breast cancer genes Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a high fatality rate. Currently, chemotherapy is the major treatment option, but the clinical result is unsatisfactory. A research team led by biologists at City University of Hong Kong (CityU) has identified and characterized a set of specific super-enhancers that stimulate the activity of the related critical cancer genes. The research has also discovered that the deletion of certain specific super-enhancers can reduce...

Scientists compare DNA damaging properties of chemicals from vape products and cigarettes Imperial Brands scientists have utilized Toxys' ToxTracker suite of stem-cell based in-vitro assays, which provide mechanistic insight into the potential DNA damaging properties of chemicals, comparing vape e-liquid samples and their aerosols to combustible cigarette smoke. Imperial scientists are the first to publish results using the ToxTracker system for the assessment of vape e-liquids and aerosols, and it forms part of the company's continuing research into the tobacco harm reduction potential of Ne...

Vaccines are an important tool in fighting porcine reproductive and respiratory syndrome, but the fast-mutating virus that causes the disease sometimes requires the production of autogenous vaccines tailored to particular variants. The production of autogenous vaccines depends on the ability of scientists to isolate the virus, but sometimes that’s a tricky process. A new study from an Iowa State University researcher shows that a new cell line may offer a better alternative to the cell line most commonly used to isolate the PRRS virus. That could lead to more reliable processes for creat...

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.